16 April 2024 - Selarsdi is expected to be marketed in the US on or after 21 February 2025, following a settlement agreement with Johnson & Johnson, the manufacturer of Stelara.

Alvotech and Teva Pharmaceuticals today announced that the US FDA has approved Selarsdi (ustekinumab-aekn) injection for subcutaneous use, as a biosimilar to Stelara, for the treatment of moderate to severe plaque psoriasis and for active psoriatic arthritis in adults and paediatric patients 6 years and older.

Read Alvotech press release